Comparison 7. Secondary outcome ‐ PASI 90 at 52 weeks.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7.1 Biologic 1 versus biologic 2	17	8729	Risk Ratio (M‐H, Random, 95% CI)	1.20 [1.09, 1.32]
7.1.1 Secukinumab versus ustekinumab	2	1778	Risk Ratio (M‐H, Random, 95% CI)	1.23 [1.15, 1.31]
7.1.2 Risankizumab versus ustekinumab	2	799	Risk Ratio (M‐H, Random, 95% CI)	1.73 [1.46, 2.05]
7.1.3 Ixekizumab versus ustekinumab	1	302	Risk Ratio (M‐H, Random, 95% CI)	1.30 [1.11, 1.52]
7.1.4 Bimekizumab versus ustekinumab	1	484	Risk Ratio (M‐H, Random, 95% CI)	1.47 [1.27, 1.70]
7.1.5 Risankizumab versus secukinumab	1	327	Risk Ratio (M‐H, Random, 95% CI)	1.52 [1.31, 1.76]
7.1.6 Bimekizumab versus secukinumab	1	743	Risk Ratio (M‐H, Random, 95% CI)	1.19 [1.09, 1.28]
7.1.7 Guselkumab versus secukinumab	1	1048	Risk Ratio (M‐H, Random, 95% CI)	1.21 [1.13, 1.29]
7.1.8 Guselkumab versus adalimumab	1	663	Risk Ratio (M‐H, Random, 95% CI)	1.59 [1.40, 1.81]
7.1.9 Ixekizumab versus adalimumab	1	100	Risk Ratio (M‐H, Random, 95% CI)	1.34 [1.04, 1.74]
7.1.10 Secukinumab 150 versus secukinumab 300	3	1017	Risk Ratio (M‐H, Random, 95% CI)	0.84 [0.78, 0.91]
7.1.11 Guselkumab 100 versus guselkumab 50	1	128	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.85, 1.25]
7.1.12 Ixekizumab Q2W versus Ixekizumab Q4W	1	1227	Risk Ratio (M‐H, Random, 95% CI)	1.06 [1.01, 1.11]
7.1.13 Risankizumab 75 versus risankizumab 150	1	113	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.82, 1.06]
7.2 Small molecule 1 versus small molecule 2	1	170	Risk Ratio (M‐H, Random, 95% CI)	1.25 [0.84, 1.86]
7.2.1 Apremilast 30 mg versus apremilast other	1	170	Risk Ratio (M‐H, Random, 95% CI)	1.25 [0.84, 1.86]